AZN.L - AstraZeneca PLC
| Previous close | 6,821.00 |
| Open | 6,821.00 |
| Bid | 6,791.00 x 0 |
| Ask | 6,790.00 x 0 |
| Day's range | 6,763.00 - 6,860.00 |
| 52-week range | 5,312.00 - 8,227.88 |
| Volume | 1,344,928 |
| Avg. volume | 2,362,770 |
| Market cap | 88.841B |
| Beta (3Y monthly) | 0.91 |
| PE ratio (TTM) | 39.56 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.19 (3.21%) |
| Ex-dividend date | 2019-08-08 |
| 1y target est | N/A |
- Business Wire
FDA Grants Fast Track Designation for FARXIGA in Heart Failure
AstraZeneca today announced that the US Food and Drug Administration has granted Fast Track designation for the development of FARXIGA to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced ejection fraction or preserved ejection fraction .
- Business Wire
IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone
- Business Wire
IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer
Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer
- Business Wire
CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine
- Business Wire
LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis
In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo
- Business Wire
FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes
FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58
- Business Wire
IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer
Data presented at ASCO 2019 showed 57% of patients alive at three years vs. 43.5% on placebo
- Business Wire
Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative to Empower and Unite Heart Attack Survivors Nationwide
AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite heart attack survivors nationwide and elevate the importance of daily heart health management. The tour will kick off with a stop in Tampa, Florida, on June 5th, connecting local survivors with Bob Harper to share stories of strength and resilience. Further, the Survivors Have Heart initiative will bring together cardiovascular patient advocacy organizations, healthcare providers, policymakers and other community leaders to celebrate survivorship and champion the importance of cardiovascular health as part of a long-term healthy lifestyle.
- Business Wire
FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma
A new integrated analysis of Phase III data for FASENRA® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and experienced a sustained improvement in exacerbation rates, lung function, asthma control and health-related quality of life. The analysis, presented today at the American Thoracic Society (ATS) 2019 International Conference, provides long-term efficacy and safety data for FASENRA from the one-year Phase III SIROCCO and CALIMA exacerbation trials, the one-year Phase III BORA extension trial and the 28-week Phase III ZONDA OCS-sparing trial.
- Business Wire
AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting
Data focused on breaking treatment boundaries, treating patients earlier in their disease, and raising the bar for better outcomes
- Business Wire
AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer
AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing (sometimes referred to as molecular testing or mutation testing), which can help patients and their physician find the treatment options that are right for them. AstraZeneca is partnering with the world-renowned golf pro to launch the Test It Back campaign, focused on ensuring complete biomarker testing becomes standard of care at every late-stage lung cancer diagnosis. The Test It Back site includes a series of inspiring videos featuring Day and his mother, Dening, whose decision to get mutation testing of her Stage IV non-small cell lung cancer last year informed her treatment decisions.
- Business Wire
Change Makers Across the Oncology Community Recognized at 2019 Cancer Community (C2) Awards
The oncology community gathered together last night to celebrate the winners of the first Cancer Community (C2) Awards. The awards – a partnership between AstraZeneca and Scientific American Custom Media – includes nominations submitted by organizations from across the cancer ecosystem and participation from an esteemed panel of third-party judges. “There is so much progress happening in cancer care, but it takes a village to make real change,” expressed Olivier Nataf, Head of US Oncology, AstraZeneca.
- EQS Group
Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales
Hardman & Co Research 09-Apr-2019 / 16:10 GMT/BST * * *Hardman & Co Research: Global Pharmaceuticals: 2018 industry salesOver the last few weeks, most of the multi-national pharmaceutical companies have reported results for 2018, which has given us the opportunity to update our industry statistics and drug database. This report provides the first publication of global and US rankings of the top 15 drug companies for 2018. Comparisons are made with historical data to show how different company strategies have evolved. In addition, analysis has been provided for the evolution of therapeutic biopharmaceutical drugs, which saw sales rise 7.5% to $219bn, representing 25% of the market, and driven by growth in antibody-derived drugs.Companies (Ticker ISIN) mentioned in this report: AbbVie (ABBV US00287Y1091), Amgen (AMGN US0311621009), AstraZeneca (AZN GB0009895292), Bayer (BAYGN DE000BAY0017), Bristol-Myers Squibb (BMY US1101221083), Celgene (CELG US1510201049), Gilead Sciences (GILD US3755581036), GlaxoSmithKline (GSK GB0009252882), Johnson & Johnson (JNJ US4781601046), Eli Lilly (LLY US5324571083), Merck & Co (MRK US58933Y1055), Novartis (NOVN CH0012005267), Novo Nordisk (NOVO DK0060534915), Pfizer (PFE US7170811035), Roche (ROG CH0012032113), Sanofi (SAN FR0000120578), Takeda (4502 JP3463000004), Teva (TEVA US8816242098). Please click here for the full report:https://www.hardmanandco.com/research/corporate-research/global-pharmaceuticals-2018-industry-statistics/To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.com Follow us on Twitter @HardmanandCo Contacts: Martin Hall +44 20 7194 7632 mh@hardmanandco.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
- Business Wire
Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational MEK 1/2 inhibitor and potential new medicine selumetinib.
- Business Wire
First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes
FARXIGA reduced major adverse cardiovascular events by 16% in patients who had a prior heart attack
- Business Wire
AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019
First sub-analyses from Phase III DECLARE-TIMI 58 trial selected for late-breaking clinical trial and oral presentations
- GlobeNewswire
Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK
PRESS RELEASE: REGULATED INFORMATION Thursday, 28 February 2019, 07:00 CET BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK Mechelen, Belgium , 28 February 2019 - Biocartis Group NV (the `Company` ...